Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading 5.3% Higher - Should You Buy?

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) was up 5.3% during mid-day trading on Monday . The company traded as high as $0.49 and last traded at $0.49. Approximately 1,500 shares traded hands during mid-day trading, a decline of 29% from the average daily volume of 2,100 shares. The stock had previously closed at $0.47.

Sino Biopharmaceutical Trading Up 0.5%

The company has a current ratio of 1.15, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $0.46 and a 200-day moving average price of $0.43.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.